Fate Therapeutics Announces Interim Data From Ongoing Phase 2 PUMA Study
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established procedure performed with curative intent in patients with a wide range of hematologic malignancies and life-threatening inherited immune and blood disorders. More than 20,000 ...
MarketWatch - Thu, 18 Dec 2014 04:03

Bayer Appoints Cardinal Health as U.S. Based Contract Manufacturer for ...
Xofigo is an alpha-particle-emitting radioactive therapeutic agent for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Bayer HealthCare is developing ...
CNNMoney - Thu, 18 Dec 2014 09:15

Stroke Can Occur at Any Age
These included sex, diagnoses of immunologic, hematologic, or cardiac disease, or records indicating head or neck trauma in the preceding month. In 72 cases, the records included results of imaging scans. These showed signs of arteriopathy in 28 cases; ...
MedPage Today - Wed, 17 Dec 2014 16:33

Early thymic precursor immunophenotype does not affect T-cell ALL outcomes
The presence of minimal residual disease in the bone marrow at day 29 after induction therapy or at the end of consolidation therapy were both associated with a poorer outcome; however, minimal residual disease in the peripheral blood at day 8 did not ...
Healio - Thu, 18 Dec 2014 07:33

An All-Oral Therapy Tested in Multiple Myeloma
SAN FRANCISCO — The first all-oral regimen for the treatment multiple myeloma could be on the way to the clinic, according to early data presented here at the American Society of Hematology 56th Annual Meeting. In a phase 2 study, treatment-naïve ...
Medscape - Wed, 17 Dec 2014 12:26

87% Complete Remission Rate With Nilotinib in ALL
The data, from an interim analysis of the ongoing phase 2 trial of the European Working Group for Adult ALL (EWALL), were reported here at the American Society of Hematology 56th Annual Meeting. These early results could point the way toward a usable ...
Medscape - Wed, 17 Dec 2014 10:33



The Year in Hematologic Malignancies
The problem is that some of those changes, such as renal insufficiency and bone disease, can be debilitating once they occur," said Dr Kumar. "The new guidelines move the bar for treating a little lower. Now, if clinicians see bone marrow plasma cells ...
Medscape - Thu, 11 Dec 2014 11:07

The Zacks Analyst Blog Highlights: Gilead, Biogen, AbbVie and Shire
Cambridge, MA-based Biogen (Nasdaq: BIIB-Free Report), which focuses on the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders, also had a good run this year. The company, which specializes in multiple ...
PR Newswire (press release) - Wed, 17 Dec 2014 06:26


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014